



CTT Pharma Gives Update On NSF Grant For Smoke Reduction Technology

Tampa, Florida, United States – The Newswire – June 24, 2024 - CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) submitted a full proposal to the National Science Foundation(NSF) for our patented fast dissolving nicotine strips. The NSF grant program is highly competitive as it receives over 12,000 applicants annually from companies that have innovations that could help society. CTT successfully made it past the first round process and is among a few thousand remaining applicants. These remaining applicants have several deadlines over the course of the year to file a full proposal into the grant program. CTT successfully met the March 4th deadline and is anticipating an answer in the last week of August or the first week of September. Successful entry into the all three phases with the NSF grant program would allow CTT funding for the creation of our technology, research/testing, and mass production of our low dose fast acting dissolvable nicotine strips.

The World Health Organization states, “The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non-smokers being exposed to second-hand smoke.” Furthermore, the CDC says, “Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly 1 in 5 deaths.

The CEO of CTT Pharma, Ryan Khouri, stated to make it past the first round of applicants is a huge accomplishment by itself and shows that the NSF sees value for our technology within the tobacco industry. Currently there are no fast dissolving, low dose nicotine strips on the market, as most oral products stay in the mouth for an excessive amount of time. I'm optimistic about this opportunity and will continue to pursue the NSF in the event that we do not get approval. I want shareholders to know that we will also give updates on our NIH Grants in the near future. The NIH Grant is a \$15 million award for a smoking cessation product that would involve human trials with Johns Hopkins University using our patented technology. The other grant is for a \$2.3 million and is for a diabetes patients using liraglutide on a dissolvable strip and potentially allowing diabetic patients and people battling obesity an alternative to daily or weekly injections.